Choate Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Choate Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,304	Closed	-$214K	–	447
2025 Q3	$214K	Buy	+3,304	New	+$190K	﹤0.01%	399
2024 Q2	–	Sell	-3,654	Closed	-$249K	–	383
2024 Q1	$249K	Hold	3,654	–	–	0.01%	357
2023 Q4	$229K	Buy	+3,654	New	+$202K	0.01%	345
2021 Q3	–	Sell	-1,704	Closed	-$276K	–	311
2021 Q2	$276K	Buy	+1,704	New	+$207K	0.02%	236

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Choate Investment Advisors's CRSP Position: Q4 2025 in Review

Choate Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,304 shares — an estimated $214K sold.

Choate Investment Advisors first reported a position in CRSP in Q2 2021 and held it in 4 quarters. The position peaked at $276K in Q2 2021. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Choate Investment Advisors reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Choate Investment Advisors sold 3,304 CRISPR Therapeutics shares in Q4 2025, an estimated $214K.
Choate Investment Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 4 quarters.
Choate Investment Advisors's CRISPR Therapeutics position peaked at $276K in Q2 2021.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Choate Investment Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.